Open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and many other nations and is the leading cause of blindness in African Americans. Elevated intraocular pressure (ocular hypertension or OHT) is a major risk factor for developing POAG and the only modifiable risk factor at present. 4-7% of the United States population above age 40 has OHT. A major public health issue is how to apply the principles of patient- centered care and manage this large group of people in an effective and cost-effective manner. The OHTS carefully followed OHT participants for a median of 13 years. (OHTS Phase 1 and 2) This includes 279 participants who developed POAG during the study, the largest inception cohort of POAG patients ever described. We propose to re-examine all surviving OHTS participants at 20 years or more in 2015-2017 (OHTS Phase 3). We will determine the incidence and severity of POAG in the OHTS cohort and determine the frequency and severity of self-reported functional limitations associated with POAG. We will also develop a 20-year prediction model for stratifying OHT patients by their risk of developing POAG and, among those who developed POAG, a prediction model for the rate of visual field loss. OHTS Phase 3 will allow us to develop evidence-based, 20-year guidelines for the management of patients with OHT. This will aid patients and clinicians to make informed decisions about the appropriate frequency of examinations and tests and the benefit of early, preventative treatment. Informed decisions should improve outcomes, reduce costs and reduce patient and clinician burden.
We will re-examine participants in the Ocular Hypertension Treatment Study (OHTS) after 20 years or more of follow-up to determine the incidence and severity of primary open angle glaucoma (POAG) in the cohort and determine the frequency and severity of self-reported functional limitations associated with POAG. We will also develop a 20-year prediction model for stratifying ocular hypertensive patients by their risk of developing POAG and, among those who developed POAG, a prediction model for the rate of visual field loss.
|Gordon, Mae O; Higginbotham, Eve J; Heuer, Dale K et al. (2018) Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study. Am J Ophthalmol :|
|Gordon, Mae O; Kass, Michael A (2018) What We Have Learned From the Ocular Hypertension Treatment Study. Am J Ophthalmol 189:xxiv-xxvii|
|Scheetz, Todd E; Faga, Ben; Ortega, Lizette et al. (2016) Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. Ophthalmology 123:2527-2536|
|Parrish 2nd, Richard K (2016) Your American Journal of Ophthalmology: The Next Chapter. Am J Ophthalmol 163:x-xi|
|Gardiner, Stuart K; Demirel, Shaban; De Moraes, Carlos Gustavo et al. (2013) Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci 54:1252-9|
|Zangwill, Linda M; Jain, Sonia; Dirkes, Keri et al. (2013) The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Am J Ophthalmol 155:971-82|
|Mansberger, Steven L; Gordon, Mae O; Jampel, Henry et al. (2012) Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology 119:1826-31|
|Weinreb, Robert N; Zangwill, Linda M; Jain, Sonia et al. (2010) Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study. Ophthalmology 117:1674-83|
|Artes, Paul H; Chauhan, Balwantray C; Keltner, John L et al. (2010) Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol 128:1528-32|